Links to PamGene Posters
Below you will find links for direct download of Scientific Posters presented by PamGene and our collaborators.
2017 AACR (American Association of Cancer Research) Immune system pathway activation for prediction of the response to neoadjuvant chemotherapy in triple-negative breast cancer 
Sawada T et al
 
2017 AACR (American Association of Cancer Research) Discovery of a kinome signature predicting sensitivity and resistance to RAF-MAPK pathway inhibitors in melanoma
Hilhorst R et al
 
2017 AACR (American Association of Cancer Research)
 
Correlation of phosphatase activity with lymphocyte infiltrates in metastatic renal cell carcinoma tissues 
Ruijtenbeek R et al
 
2017 AACR (American Association of Cancer Research) Comprehensive high-throughput screen for combination therapies to block acquired resistance to targeted drugs
Haviv I
 
2017 AACR (American Association of Cancer Research) A kinome analysis of the molecular pharmacodynamics of PT-112 in a human cancer cell line
Tosi D et al
 
2017 SOT (Society of Toxicology) Identification of Novel Chemical Modulators of Estrogen Receptor α (ERα) in a Gene Expression Compendium. 
Rooney J et al
 
 
2017 ENETS (European Neuroendocrine Tumour Society) Identification of novel therapeutic targets by kinomic profiling of drug resistant neuroendocrine tumors
Romano D et al
 
 
2016 AACR (American Association of Cancer Research) Sunitinib impact on kinome profiles of peripheral blood mononuclear cells from renal cell carcinoma patients: Do molecular effects correlate with clinical data?
Bellesoeur A et al
 
2016 TAT (Targeted Anticancer Therapies) Blocking the stress specific APIM-PCNA interaction increases the efficacy of cancer therapies 
Søgaard CD et al 
 
2015 Elrig Drug Discovery PamGene’s Kinase activity profiling of tumor tissues of different origin (145)
Rampling E et al.
 
2015  BioSB Conference Upstream kinase analysis of kinase activity profiles obtained with a peptide microarray.
de Wijn R et al.
 
2015 AACR (American Association of Cancer Research) Kinase activity profiles distinguish papillary thyroid cancers with and without BRAF V600E mutations.
Hilhorst MH et al.
 
2015 AACR (American Association of Cancer Research) Predicting clinical response based on ex vivo drug response in renal cell carcinoma using kinase activity profiling.
Ruijtenbeek R et al.
 
2015 AACR (American Association of Cancer Research) Profiling drug sensitivity and kinomic pathways utilizing a novel human tumor derived MicroTumor assay.
Willey CD et al.
 
2015 SOT (Society of Toxicology) (Ant)agonist-Induced Modulation of ERα and ERβ Cointeraction.
de Haan L et al.
 
2015 SOT (Society of Toxicology) Functional characterization of compounds by their ability to modulate Farnesoid X receptor interaction with a coregulator motif peptide array reveals multiple modes of action.
Houtman, R et al.
 
2014 AACR (American Association of Cancer Research) Kinase activity profiling combined with genotyping as a tool for predictive biomarker discovery for the treatment of gastroesophageal adenocarcinoma (GEC).
Catenacci DVT et al.
 
2014 AACR (American Association of Cancer Research) Direct effect of regorafenib on tyrosine kinase activities in treatment naive colorectal cancer (CRC) primary tumor tissue.
Hilhorst MH et al.
 
2014 AACR (American Association of Cancer Research) Predictive signature of response to EGFR tyrosine kinase inhibitors in non-small-cell lung cancer cells by tyrosine kinase activity profiling.
Izawa N et al.
 
2014 AACR (American Association of Cancer Research) Co-treatment with simvastatin and cetuximab in KRAS mutant LoVo cells decreases PTK activity effectively and increases STK activity to overcome the anti-EGFR resistance.
Krens L et al.
 
2014 I4H (Innovation for Health)
 
Innovative protein kinase activity profiling of patients with Alzheimer’s disease reveals pathway changes.
Rosenberger AFN et al.
 
2014 Keystone Symposia (Nuclear Receptors: Biological Networks, Genome Dynamics and Disease)
 
Combined ERα- and kinase-activity profiling in primary tissue of a refractory breast cancer patient.
Houtman R et al.
2014 SOT (Society of Toxicology) Profiling of Compound-Induced Modulation of CAR-Coregulator Interactions As a Means to Differentiate between Direct and Indirect CAR Activation.
Groten JP et al.
 
2014 SOT (Society of Toxicology) Profiling of Compound-Induced Modulation of ERalpha-Coregulator Interaction As a Means to Compare Bisphenol A Analogs. 
Houtman R et al.
 
2014 SOT (Society of Toxicology) Thalidomide Increases Cytochrome P450 Activity and Drug Metabolism in Liver through Direct Activation of Nuclear Receptor CAR and PXR.
van Beuningen R et al. 
 
2013 AACR (American Association of Cancer Research) Protein tyrosine kinase substrates profiling to detect short-term survivors in early stage lung adenocarcinoma. 
Arni S et al.
 
2013 AACR (American Association of Cancer Research) In vitro tyrosine kinase activity profiling to identify molecular targets and predictive biomarkers in gastric cancer cell lines. Koh Y et al.
 
2013 AACR (American Association of Cancer Research) Inter-patient differences in colon tumors reflected in kinase activity and inhibition profiles related to KRAS and BRAF mutation status
van den Oord R et al.
 
2013 AACR (American Association of Cancer Research)
 
Sunitinib inhibits AXL phosphorylation in tumor cells. 
van der Mijn JC et al.
2013 AACR (American Association of Cancer Research) Development of a new and sensitive detection technology for galectin cancer proteins.
van hattum H et al.
 
2013 Congress on Steroid Research A 155-plex high-throughput in vitro coregulator binding assay for (anti-)estrogenicity testing evaluated with 23 reference compounds.
Wang S et al.
 
2013 EMBC (European Molecular Biology Conference)  Combined ERα- and kinase-activity profiling in primary tissue of a refractory breast cancer patient.
Houtman R et al.
 
2013 SOT (Society of Toxicology) Profiling of ERα-coregulator binding as a means for functional classification of unknown endocrine disruptors.
Houtman R et al. 
 
2012 AACR (American Association of Cancer Research) Pre-clinical and molecular analysis of Crizotinib in c-Met positive uveal melanoma.
de Lange MJ et al.
 
2012 AACR (American Association of Cancer Research) ALK F1174L kinase activity as driver of cell proliferation in neuroblastoma cell line models and neuroblastoma tumors. 
Hilhorst R et al. 
 
2012 AACR (American Association of Cancer Research) Measurement of kinase activity in cancer cell lines and tumor tissue using a tyrosine kinase peptide substrate array.
Labots M et al. 
 
2012 AACR (American Association of Cancer Research) Tyrosine kinase activity profiling of metastatic malignant melanoma: Identification of possible therapeutic targets and markers predicting response to therapy.
Tahiri A et al.
 
2012 SOT (Society of Toxicology) ERα MARCoNI as an in vitro alternative for the rat uterotrophic assay for Endocrine disruptors.
Houtman R et al.
 
2012 SOT (Society of Toxicology) Kinase activity profiling in investigative toxicology.
Lord, P et al.
 
2012 WIN Symposium (Worldwide Innovative Networking) Response prediction using ex vivo PamChip assays for activity-based testing of drug-target interactions in patient-derived tumor lysates.
Hilhorst R et al.
 
2011 AACR (American Association of Cancer Research) Direct detection of AKT/PKB activity in a PTEN knock out mouse model using dynamic peptide microarrays.
Hilhorst R et al.

 
2011 AACR (American Association of Cancer Research) In vitro evaluation of multi-targeted kinase inhibitors in scirrhous gastric cancer cell lines by tyrosine kinase activity profiling.
Koh Y et al.
 
2011 AACR (American Association of Cancer Research) Two case studies on kinase activity profiling in non-small cell lung carcinoma tumour tissues: Identification of prognostic biomarkers and Identification of biomarkers that predict response to erlotinib treatment.
Ruijtenbeek R et al.
 
2011 AACR (American Association of Cancer Research) Tumor kinome profiling of early systemic disease dissemination in rectal cancer – signaling mediated by PDGFR, VEGFR, and EPOR
Saelen MG et al.
 
2011 ASCO (American Society of Clinical Oncologists) Blind prediction of response to erlotinib in early stage non small cell lung cancer (NSCLC) in a neoadjuvant setting based on kinase activity profiles.
Hilhorst R et al.
 
2011 CHAINS (Chemistry as an innovating science) Protein kinase activity profiling to find diagnostic biomarkers for Alzheimer’s disease.
Rosenberger AFN et al.
 
2011 CTMM (Center for Translational Molecular Medicine) PamGene kinase peptide array technology for identification of clinically relevant biomarkers in rheumatoid arthritis.  
Wesseling JG et al.
 
2011 ESMO (European Society for Medical Oncology) Identification of a protein kinase activity based biomarker fingerprint to predict response to sunitinib, sorafenib and pazopanib in scirrhous gastric cancer cell lines. 
Koh Y et al.
 
2011 Molecular Targets and Cancer Therapeutics Conference Ex vivo kinome profiling of tumors from rectal cancer patients for possible identification of functional biomarkers of EGFR signaling pathway druggability.
Ree AH et al.
 
2011 Nordic Proteomics Symposium Tumor tissue profiling at the drug targeting level: kinase activity profiling.
Ruijtenbeek R et al.
 
2011 TAT (Targeted Anticancer Therapies) A promising approach towards personalized targeted therapy for pancreatic cancer using an innovative kinase activity profiling assay.
Rangarajan S et al.
 
2010 AACR (American Association of Cancer Research) Response prediction to a multitargeted tyrosine kinase inhibitor by profiling serine/threonine kinase activity and inhibition.
Hilhorst et al.
 
2010 AACR (American Association of Cancer Research)
 
Kinase activity profiling of tumor tissues of diffferent origin.
Ruijtenbeek R et al.
2010 ASCO (American Society of Clinical Oncologists) Application of kinase activity profiles to predict response to erlotinib in a neoadjuvant setting in early stage non-small cell lung cancer (NSCLC).
Hilhorst et al.
 
2010 ENA (EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics)
 
The potential to personalize targeted therapy shown by in vitro kinase activity profiling in pancreatic xenograft models.
Rangarajan S et al.
2010 NCRI (National Cancer Research Institute) Identification of prognostic biomarkers and Identification of biomarkers that predict response to erlotinib treatment.
Ruijtenbeek R et al.
 
2009 AACR (American Association of Cancer Research) Multiplex protein tyrosine kinase activity profiling of breast cancer cell lines and tumors tissues on a peptide microarray.
Hilhorst et al.
 
2009 AACR (American Association of Cancer Research) Tyrosine kinase activity profiling of tumor tissues from Renal cell carcinoma patients.
Ruijtenbeek R et al.
 
2009 WCLC (World Conference on Lung Cancer) Application of kinase activity profiles to predict survival and therapeutic strategies in early stage non small cell lung cancer.
Hilhorst et al.